olmesartan has been researched along with topotecan in 3 studies
Studies (olmesartan) | Trials (olmesartan) | Recent Studies (post-2010) (olmesartan) | Studies (topotecan) | Trials (topotecan) | Recent Studies (post-2010) (topotecan) |
---|---|---|---|---|---|
841 | 185 | 554 | 2,392 | 626 | 792 |
Protein | Taxonomy | olmesartan (IC50) | topotecan (IC50) |
---|---|---|---|
Cytochrome P450 3A4 | Homo sapiens (human) | 1.5211 | |
DNA topoisomerase 1 | Homo sapiens (human) | 0.8525 | |
DNA topoisomerase 2-alpha | Homo sapiens (human) | 0.605 | |
DNA topoisomerase 2-beta | Homo sapiens (human) | 0.605 | |
Hypoxia-inducible factor 1-alpha | Homo sapiens (human) | 0.06 | |
Multidrug and toxin extrusion protein 2 | Homo sapiens (human) | 8.6 | |
Multidrug and toxin extrusion protein 1 | Homo sapiens (human) | 1.3 | |
Broad substrate specificity ATP-binding cassette transporter ABCG2 | Homo sapiens (human) | 0.17 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (33.33) | 29.6817 |
2010's | 2 (66.67) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Andricopulo, AD; Moda, TL; Montanari, CA | 1 |
Benet, LZ; Brouwer, KL; Chu, X; Dahlin, A; Evers, R; Fischer, V; Giacomini, KM; Hillgren, KM; Hoffmaster, KA; Huang, SM; Ishikawa, T; Keppler, D; Kim, RB; Lee, CA; Niemi, M; Polli, JW; Sugiyama, Y; Swaan, PW; Tweedie, DJ; Ware, JA; Wright, SH; Yee, SW; Zamek-Gliszczynski, MJ; Zhang, L | 1 |
Amano, N; Maeda, K; Moriwaki, T; Nakakariya, M; Ono, M; Sugiyama, Y | 1 |
1 review(s) available for olmesartan and topotecan
Article | Year |
---|---|
Membrane transporters in drug development.
Topics: Animals; Computer Simulation; Decision Trees; Drug Approval; Drug Discovery; Drug Evaluation, Preclinical; Drug Interactions; Humans; Membrane Transport Proteins; Mice; Mice, Knockout; Prescription Drugs | 2010 |
2 other study(ies) available for olmesartan and topotecan
Article | Year |
---|---|
Hologram QSAR model for the prediction of human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Holography; Humans; Models, Biological; Models, Molecular; Molecular Structure; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship | 2007 |
In vivo biliary clearance should be predicted by intrinsic biliary clearance in sandwich-cultured hepatocytes.
Topics: Angiotensin Receptor Antagonists; Animals; beta-Lactams; Biliary Tract; Biological Transport; Cells, Cultured; Hepatocytes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Pharmaceutical Preparations; Rats; Rats, Sprague-Dawley; Topotecan | 2012 |